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Purpose: To treat malaria, HIV-infected patients normally receive artemether (80 mg twice daily) concurrently with
antiretroviral therapy and drug-drug interactions can potentially occur. Artemether is a substrate of CYP3A4 and
CYP2B6, antiretrovirals such as efavirenz induce these enzymes and have the potential to reduce artemether
pharmacokinetic exposure. The aim of this study was to develop an in vitro in vivo extrapolation (IVIVE) approach to
model the interaction between efavirenz and artemether. Artemether dose adjustments were then simulated in
order to predict optimal dosing in co-infected patients and inform future interaction study design.
Methods: In vitro data describing the chemical properties, absorption, distribution, metabolism and elimination of
efavirenz and artemether were obtained from published literature and included in a physiologically based
pharmacokinetic model (PBPK) to predict drug disposition simulating virtual clinical trials. Administration of
efavirenz and artemether, alone or in combination, were simulated to mirror previous clinical studies and facilitate
validation of the model and realistic interpretation of the simulation. Efavirenz (600 mg once daily) was
administered to 50 virtual subjects for 14 days. This was followed by concomitant administration of artemether
(80 mg eight hourly) for the first two doses and 80 mg (twice daily) for another two days.
Results: Simulated pharmacokinetics and the drug-drug interaction were in concordance with available clinical
data. Efavirenz induced first pass metabolism and hepatic clearance, reducing artemether Cmax by 60% and AUC by
80%. Dose increases of artemether, to correct for the interaction, were simulated and a dose of 240 mg was
predicted to be sufficient to overcome the interaction and allow therapeutic plasma concentrations of artemether.
Conclusions: The model presented here provides a rational platform to inform the design for a clinical drug
interaction study that may save time and resource while the optimal dose is determined empirically. Wider
application of IVIVE could help researchers gain a better understanding of the molecular mechanisms underpinning
variability in drug disposition.
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The geographical overlap in the prevalence, morbidity and
mortality of malaria and HIV constitutes a major public
health burden in low- and middle-income countries. In
2010 alone, more than 34 million people were living with
HIV worldwide (68% in Sub-Saharan Africa) and approxi-
mately 1.8 million died of AIDS-related illnesses (UNAIDS
2010). Malaria caused an estimated 219 million acute
illnesses and 660,000 deaths in the same year (WHO 2012).
Approximately 80% of these cases and 90% of deaths oc-
curred in Sub-Saharan Africa, disproportionately affecting
children less than 5 years old and pregnant women (WHO
2012). Jointly accounting for about 2.5 million deaths in
2010 alone, there is little doubt over the public health
consequences of these diseases.
Limited access to highly active antiretroviral therapy
(HAART) in low and middle income countries constitutes
a major barrier that substantially diminishes the number of
therapeutic options available. Therefore, protection of cur-
rently available first-line antiretroviral and antimalarial
drugs against resistance is of paramount importance (Vella
et al. 2012). HAART is based on the combination of differ-
ent classes of drugs and in resource-limited countries (as
elsewhere), regimens including the non-nucleoside reverse
transcriptase inhibitors (NNRTIs), nevirapine and efavirenz,
are indicated as first-line therapies.
Artemether/lumefantrine, the first-line artemisinin-
based combination therapy (ACT) for treatment of
malaria, is currently administered concomitantly with
HAART in co-infected patients in several African
countries. A six-dose regimen administered over three
days has excellent efficacy against plasmodium falciparum
malaria. Co-infection with malaria and HIV has been
shown to impact negatively on the course of both infections
(WHO 2005). Gonzalez et al. recently provided a compre-
hensive review of the epidemiological, clinical, immuno-
logical and therapeutic interactions between malaria
and HIV (Gonzalez et al. 2012). Unfortunately, avail-
able treatment options in high burden countries are
limited and development of effective treatment strategies
that protect available first-line drugs is paramount as
second line drugs are more costly and frequently
unavailable.
Artemether is a substrate for cytochrome P450 3A4
(CYP3A4) and CYP2B6, and is quickly absorbed in the first
two to three hours after oral administration. Bioavailability
is low due to intestinal and first-pass hepatic metabolism
(Byakika-Kibwika et al. 2012). Antiretrovirals induce or
inhibit hepatic CYPs and therefore have the potential to
cause several drug drug interactions. More specifically,
boosted PI can cause significant drug interactions due to
the potent inhibition of CYP3A4 by ritonavir (RTV) and
efavirenz and nevirapine can induce the expression of
several CYPs. Drug-drug interactions have been describedfor several class of drugs such as, immunosuppressants,
statins, antipsychotics, antifungals and antibacterials.
(Marzolini et al. 2010). EFV is thought to reduce
bioavailability and increase hepatic clearance of arte-
mether, thereby reducing plasma exposure. Recently,
Byakika-Kibwika et al. reported 59% and 79% reductions
in artemether Cmax and plasma AUC, respectively, when
co-administered with efavirenz in HIV-infected adults
(Byakika-Kibwika et al. 2012). Similarly, Huang et al.
reported a 51% decrease in artemether AUC when co-
administered with efavirenz in healthy volunteers (Huang
et al. 2012). Since efavirenz-containing regimens are
preferred for patients initiating therapy, dose opti-
misation strategies to mitigate the interaction are
worthy of investigation (Best and Goicoechea 2008).
In vitro in vivo extrapolation (IVIVE) is a bottom up
technique which aims to simulate pharmacokinetics using
in vitro data, such as the physicochemical characteristics
and intrinsic clearance (CLint) through physiologically-
based pharmacokinetic (PBPK) models, which mathema-
tically describe absorption, distribution, metabolism and
elimination (ADME). Therapeutic agents can be adminis-
tered via different routes and absorption can be simulated
taking into account the dynamic interplay between
dissolution, passive permeability and affinity/activity
of metabolic enzymes and transporters. For instance,
oral bioavailability (Foral) can be influenced by tablet
dissolution and solubility, impacting the fraction of
dose available for absorption (Fa), whereas intestinal
(Fg = fraction of dose available following intestinal meta-
bolism) and first-pass hepatic metabolism (Fh = fraction of
dose available following hepatic metabolism) can reduce
the amount of drug reaching the systemic circulation
(Kimura et al. 2000). Foral can be evaluated using compart-
mental absorption and transit (CAT) models estimating the
fraction of dose absorbed and the rate of drug absorption
based on transit models. Volume of distribution is simu-
lated by evaluating tissue volumes and the diffusion of
drugs into tissues, which is influenced by physicochemical
properties defining the plasma to tissue ratio (Pt:p) as
described by Poulin and Theil (Poulin and Theil 2002).
Metabolism of drugs is the result of the activity of several
metabolic enzymes in different tissues. In vitro intrinsic
clearance data can be used to simulate hepatic clearance
considering scaling factors such as CYP isoform
abundance in microsomal protein, microsomal pro-
tein per gram of liver, liver weight, blood flow and
protein binding. Inter-patient variability is observed
in all the above mentioned processes and PBPK
models allow the introduction of anatomical and
physiological characteristics and their covariance to
build a virtual population of patients. Consequently,
PBPK models give insight into mechanisms regulating the
pharmacokinetics, can be used to predict potential
Table 1 Main model parameters and equations used to





BSA 0.007184 x BW0.425x H0.725
Wblood 3.33 x BSA-0.81 (male) 0.10
2.66 x BSA-0.46 (female)
Wlungs 10
(−2.092 + 2.1 x logH) 0.195
Wheart 10
(−2.502 + 2.13 x logH) 0.069
Wbones 10
(0.0689 + 2.67 x logH) 0.116 (m); 0.083 (f)
Wkidney 10
(−2.306 + 1.93 x logH) 0.140
Wstomach 10
(−3.266 + 2.45 x logH) 0.0965 (m); 0.0425 (f)
Wintestine 10
(−1.351 + 2.47 x logH) 0.049
Wspleen 10
(−3.123 + 2.16 x logH) 0.156
Wpancreas 10
(−3.431 + 2.43 x logH) 0.245 (m); 0.087 (f)
Wliver 10
(−0.6786 + 1.98 x logH) 0.028 (m); 0.048 (f)
Wremaining 10
(−0.072 + 1.95 x logH) 0.049






Wadipose (1.20 x BMI) – (0.7 x age) –
(3.6 x gender) + 1.4
Wmuscle remains
CO QCC × (BW) 0.75
QCadipose CO x 0.052
QCbones CO x 0.042
QCbrain CO x 0.114
QCkidney CO x 0.175
QC (total)liver CO x 0.227
QC (portal)liver CO x 0.181
QCmuscle CO x 0.191
QCskin CO x 0.058
H = height; B = brain weight at birth (405 g for males and 373 g females);
BW = body weight; QC = blood flow; CO = cardiac output.
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netic consequences of different dose strategies.
The aim of this study was to develop an IVIVE
model for efavirenz and artemether pharmacokinetics
and simulate a clinical drug interaction trial. The
IVIVE model was validated by comparison with
existing clinical data and then used to simulate
appropriate artemether dose adjustments able to achieve
therapeutic artemether exposure when co-administered
with efavirenz.
Methods
In vitro-in vivo extrapolation: system parameters
Virtual patients were generated using a population
physiology model (physB), which provides a statistical
description of the physiological and anatomical char-
acteristics in the human population, focusing on
parameters that are essential in the PBPK approach
(Bosgra et al. 2012). As summarised in Table 1, organ
weights were allometrically scaled to an individual’s
height or BSA (for skin and blood) or age plus gender
(brain) or height and body weight (adipose tissues) and
random variation was added to all parameters. Cardiac
output has been defined as QC =QCC × (body weight) 0.75
and regional blood flows were simulated as previously
described (International Life Sciences Institute and
Risk Science Institute 1994). A schematic of a PBPK
model is shown in Figure 1. The differential equations
used in these models to simulate drug distribution in
tissues have been described previously (Jones et al. 2006)
and can be represented as:
VT  dCT=dt ¼ QT  Cab  QT
 CT= Kp=B : P
   ð1Þ
where Q = blood flow, C = concentration, V = volume,
T = tissues, ab = arterial, Kp = tissue to plasma partition
coefficient, and B:P = blood to plasma ratio.
Expression of cytochrome P450 in hepatic and intes-
tinal tissue was taken from previous reports (Harbourt
et al. 2012; Houston 1994; Ohtsuki et al. 2012). Oral
bioavailability is influenced by several processes.
Experimental data such as apparent permeability in
Caco-2 cell monolayer or polar surface area and num-
ber of hydrogen bond donor atoms have been used to
derive effective permeability (Peff ) and subsequently
the constant of absorption (ka) (Gertz et al. 2010).
Tablet dissolution and poor solubility can impact the
fraction of dose available for absorption (Fa), and in-
testinal (Fh) and first-pass hepatic metabolism (Fg)
can reduce the amount of drug reaching the systemic
circulation. Tablet dissolution for artemether was
taken into account using a first-order dissolution
constant as previously described (Awofisayo et al.2012). Fg and Fh were evaluated using the following
equations (Kimura et al. 2000):
Fg ¼
Qg




Qh;portal þ Fu;h  CLint; h
ð3Þ
Where Qh,portal, Qg, Fu, CLint,h, CLint,g represent
portal blood flow to liver, blood flow to intestine,
fraction unbound in tissue, hepatic intrinsic clearance
and intestinal intrinsic clearance, respectively.
Oral absorption was simulated using a compartmental
absorption and transit model and considering a stomach
transit time of 0.5 hours and a small intestine transit time
Figure 1 Schematic representation of the physiologically based pharmacokinetic (PBPK) model structure including the most relevant
organs and the blood circulation.
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1999). The volume of distribution was simulated using the
equation developed by Poulin and Theil, calculating the
plasma to tissue ratio for each organ and considering
organ volumes originated from the population physiology
model (physB) (Poulin and Theil 2002). Hepatic clearance
(CLh) and induction of enzyme expression in liver (E) were
determined using the following equations (Obach 1999):
CLh ¼ Qh  Fu  CLint;hQh þ Fu  CLint;h
ð4Þ
Ind ¼ 1þ EMAX  Ih
EC50 þ Ih ð5Þ
Where Qh, Fu, CLint,h, EMAX, EC50 and Ih represent blood
flow to the liver, fraction unbound in blood, hepatic intrin-
sic clearance, maximum induction, concentration causing
50% of maximum induction and inducer concentrations in
the liver tissue, respectively. Induction of metabolism en-
zymes was corrected to achieve 100% induction in 14 days.
In vitro-in vivo extrapolation: drug parameters
Efavirenz and artemether pharmacokinetics were simulated
using an open source PBPK model developed using
Berkeley Madonna (version 8.3.18, University of California,
CA, USA). In vitro data describing efavirenz and arte-
mether physiochemical and metabolic characteristics and
induction potential are summarized in Table 2.
For artemether, tablet dissolution and the poor solubility
described in a previous publication were included in the
model (Awofisayo et al. 2012). Data describing the metab-
olism of efavirenz and artemether by different recom-
binant enzyme isoforms were obtained from the literature
(Belanger et al. 2009; Ogburn et al. 2010; Ward et al.2003). As described in Table 2, in vitro intrinsic clearance
(CLint) for the two compounds were included in the
model: efavirenz is hydroxylated to 7-hydroxy efavirenz by
CYP2A6, to 8-hydroxy efavirenz by CYP2B6, CYP2A6,
CYP1A2, CYP3A4 and CYP3A5, and glucuronidated by
UGT2B7 while artemether is metabolised by CYP2B6 and
CYP3A4. After correction with fraction unbound in
microsomes (measured experimentally or simulated as
previously described for non-specific binding in the
in vitro reaction (Poulin and Haddad 2011)) these data
were scaled up to hepatic or intestinal intrinsic clearance
considering the amount of microsomal protein per gram
of liver and liver weight or total content of CYP3A4 in the
intestine (Crewe et al. 2011; Proctor et al. 2004).
Virtual clinical study design
Administration of efavirenz and artemether, alone or in
combination, were simulated to mirror previous clinical
studies and facilitate validation of the model and realistic
interpretation of the simulation (Byakika-Kibwika et al.
2012; Huang et al. 2012). Efavirenz (600 mg once daily) was
administered to 50 virtual subjects (20–50 years old, 0.5
proportion females) for 14 days. This was followed by con-
comitant administration of artemether (80 mg eight hourly)
for the first two doses and 80 mg (twice daily) for another
two days. The simulated pharmacokinetics of efavirenz and
artemether were compared to previous experimental
findings. Subsequently, artemether dose adjustment was
simulated to establish doses attaining artemether exposure
equivalent to that in the absence of efavirenz.
Results and discussion
Simulated pharmacokinetics of artemether and efavirenz
were in good accordance with previously described
Table 2 Efavirenz and artemether physiochemical and metabolic characteristics
Input parameter Efavirenz Arthemether
logP 4.6 (DRUGBANK - Efavirenz) 3.4 (DRUGBANK - Artemether)
PSA 46.15 (DRUGBANK - Artemether)
Caco-2 Papp 2.5 (10-6 cm/s) (Siccardi et al. 2012)
fu 0.01 (Almond et al. 2005) 0.05 (DRUGBANK - Artemether)
Metabolism (μl/min/pmol)
rCYP2B6 CLint 0.55 (Ward et al. 2003) 9.31 (Honda et al. 2011)
rCYP1A2 CLint 0.07 (Ward et al. 2003)
rCYP2A6 CLint 0.08 (Ward et al. 2003)
rCYP3A4 CLint 0.007 (Ward et al. 2003) 1.47 (Honda et al. 2011)
rCYP3A5 CLint 0.03 (Ward et al. 2003)
CYP induction
CYP2B6 Emax 5.7 (Rekic et al. 2011)
CYP2B6 EC50 0.8 (Rekic et al. 2011)
CYP3A4 Emax 6.5 (Rekic et al. 2011)
CYP3A4 EC50 3.9 (Rekic et al. 2011)
MW, molecular weight; logP, Logarithm of the Octanol-water partition coefficient; pKa, Acid dissociation constant; fu, fraction unbound in plasma; Papp, apparent
permeability; Clint, intrinsic clearance; Indmax, Maximum induction; IndC50, inducer concentration that supports half maximal induction (μM).
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(Byakika-Kibwika et al. 2012; Huang et al. 2012). In a virtual
cohort of 50 patients treated with 80 mg of artemether
twice daily for three days the simulated median (range)
AUC was equal to 166 (55–678) vs 119 (26–917) ng/ml•h
(reference value), Cmax 30 (11–73) vs 29 (10–247) ng/ml.
Simulation of artemether drug disposition was charac-
terised by low bioavalability (Foral = 0.11), with around 14%
of the dose not absorbed (Fa = 0.86), high intestinal metab-
olism (Fg = 0.21) and high first pass metabolism (Fh = 0.60).
High apparent volume of distribution (V/F = 1640 L) was
predicted, in accordance to clinical studies. Systemic
metabolism mediated by CYP2B6 and CYP3A4 was
characterised by a high CL/F of 268 L/h.
For efavirenz (600 mg once daily), the simulated
Ctrough was equal to 2341 ± 2196 (mean ± SD) vs 1752 ±Table 3 Simulated artemether pharmacokinetic variables with
virtual patients compared to observed clinical values
Simulated (median and range) Clinical trial 1 (m(Byakika-Kibw
ART ART + EFV ART
Cmax 30 (11–73) 9 (3–33) 29 (10–247)
AUC 166 (55–678) 41 (13–228) 119 (26–917)
CL/F 268 (75–895) 1847 (221–3943) 591 (80–2273)
V/F 1604 (100–4719) 4652(1618–8624) 4523 (374–10402)
Fa 0.86 0.86 -
Fg 0.21 0.21 -
Fh 0.60 0.23 -
Cmax, maximum concentrations (ng/ml); AUC: Area Under the Curve (ng.h/ml); CL/F,
of dose absorbed; Fg, fraction of dose escaping gut metabolism; Fh, fraction of dose1001 ng/ml (reference value), AUC 76282 ± 57204 vs
57592 ± 22849 ng/ml•h, Cmax 3520 ± 2567 vs 4037 ±
1158 ng/ml (Vrouenraets et al. 2007). Efavirenz mean
oral bioavalability, Foral, was 0.39, mainly limited by partial
dose absorption (Fa of 0.45), low intestinal metabolism
(Fg = 0.95) and low first-pass metabolism (Fh = 0.93).
Apparent volume of ditribution was 150 L and systemic
metabolism, mainly mediated by CYP2B6, CYP1A2,
CYP2A6 and CYP3A4, gave a CL/F of 9.7 L/h.
Efavirenz is an inducer of CYP3A4 and CYP2B6 expres-
sion with an Emax of 6.5 and EC50 of 3.9 μM for CYP3A4
and a Indmax of 5.7 and IndC50 of 0.8 μM for CYP2B6. In
the IVIVE model, efavirenz caused an increase in CYP3A4
and CYP2B6 expression, inducing artemether rate of
metabolism with a substantial effect on first pass-
metabolism and systemic clearence. Artemether Fhand without concomitant efavirenz in a cohort of 50
edian and range)
ika et al. 2012)
Clinical trial 2 (geometric mean ± CI)
(Huang et al. 2012)
ART + EFV ART ART + EFV
12 (2–8) 21.2 (15.2-35) 16.8 (12.0-35.7)
25 (5–185) 59.5 (40.8-128) 29.4 (23.8-76.6)
2558 (414–9960) - -




apparent clearance (L/h); V/F, apparent volume of distribution L/kg; Fa, fraction
escaping first pass metabolism.
Figure 2 Simulated artemether concentration-time profile for
a dose of 80 mg twice daily with and without efavirenz.
The full black line represents the mean (± SE) simulated
concentrations and grey lines represent data observed in a
clinical study (Byakika-Kibwika et al. 2012).
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CL/F was increseasd by 6-fold. This had a major effect on
artemether pharmacokinetics reducing Cmax by 60% and
AUC by 80%.
A dose increase of artemether was simulated and a
dose of 240 mg artemether was predicted to be sufficient
to overcome the effect of efavirenz on artemether drug
disposition and consequently achieve therapeutic arte-
mether plasma concentrations. At the standard regimen
(80 mg twice daily) the simulated AUC of artemether was
equal to 166 (55–678) ng.h/mL and the interaction with
efavirenz caused a reduction to 41 (13–228) ng.h/mL. A
simulated dose increase to 160 mg twice daily gave a
median (range) artemether AUC of 77 (25–620) ng.h/ml
and a dose increase to 240 mg twice daily resulted in a
median (range) artemether AUC of 115 (53–650) ng.h/ml.
Artemether is currently coadministered with lumefantrine
and EFV has been shown to decrease lumefantrine
exposure inducing its metabolism (Byakika-Kibwika
et al. 2012).
Factors influencing drug distribution can be investi-
gated using IVIVE, through a full characterisation of thebiological processes regulating ADME. Artemether and
efavirenz represent two good examples of how a complete
knowledge of drug metabolism and physicochemical prop-
erties can allow accurate prediction of drug disposition.
Efavirenz and artemether metabolism have been investi-
gated in vitro and the main enzymes responsible for their
clearance have been identified in different studies (Ogburn
et al. 2010; Takano et al. 2006; Ward et al. 2003). Efavirenz
is metabolised by several CYPs such as CYP2B6, 1A2, 2A6
and 3A4 and artemether is metabolised in the liver and in-
testine by CYP3A4 and CYP2B6. Through activation of the
nuclear receptor constitutive androstane receptor (CAR),
efavirenz strongly influences the expression of several CYPs
and transporters. Of particular importance here, CYP2B6
and CYP3A4 activity are induced up to several fold and in-
teractions with CYP3A4 and CYP2B6 substrates have been
confirmed in several clinical studies (Esteban et al. 2008;
Faucette et al. 2007; Mouly et al. 2002).
Numerous clinical studies have described poor arte-
mether bioavailability following oral administration but to
date a comprehensive measure of its oral bioavailability has
not been completed. In our simulation we estimated a Foral
equal to 0.11 with a Fa of 0.86, Fg of 0.21 and Fh of 0.6.
Slow drug release from tablet and poor solubility are the
factors causing an incomplete absorption of the artemether
dose. To support these findings, an effect of food on
artemether absorption has been described, suggesting how
prolonged transit time in the small intestine and increased
solubility due to bile acids and fat could increase oral bio-
availability (White et al. 1999). CYP isoforms are expressed
in the small intestinal tissue and intestinal metabolism has
been identified as a major factor defining oral bioavailabil-
ity of many therapeutic agents, especially CYP3A4 sub-
strates. Artemether bioavailability is also limited by high
first-pass metabolism, and the induction of CYP3A4 and
CYP2B6 expression by efavirenz in liver tissue is the main
cause of decreased artemether Fh (0.6 to 0.23) in our simu-
lations. The induction by efavirenz was predicted to have a
major impact on the systemic clearance of artemether,
increasing plasma CL/F by 6 fold as shown in Table 3. This
model suggests that a dose increase to 240 mg of arte-
mether twice daily may correct the effect of efavirenz on
artemether pharmacokinetics, restoring sufficient drug
exposure. The model presented here provides a rational
platform to inform the design for a clinical drug interaction
study that may save time and resource while the optimum
dose is determined empirically. This study does have some
limitations Since artemether is metabolised to DHA, which
is also active against Plasmodium falciparum with compar-
able EC50 in vitro, then it may be necessary to consider
plasma concentrations of DHA to get a complete picture
of antimalarial activity (Alin et al. 1990; White et al. 1999).
Also, efavirenz is a known inducer of some UGT isoforms,
such as UGT1A9 and UGT2B7 which also contribute to
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is thought to diminish DHA concentrations increasing its
rate of metabolism in the liver and kidney. Extensive
in vitro study aimed to characterise DHA metabolism and
distribution may be necessary to develop IVIVE models for
the prediction of its pharmacokinetics. Moreover the effect
of efavirenz on expression UGTs in the kidney should be
investigated to further clarify the effect of EFV on DHA
elimination. Efflux and influx transporters can have a big
impact upon drug absorption and diffusion into tissues,
and might help to explain part of the variability observed
in efavirenz and artemether pharmacokinetics. Efavirenz is
a strong inducer of ABCB1 and other transporters. There
are currently too many gaps in knowledge of these
processes to have incorporated them into the current
model. However, in vitro investigation of artemether
could clarify the role of transporters in this or similar
drug-drug interactions (Weiss et al. 2009).
Conclusion
The developed IVIVE model accurately predicted the
pharmacokinetics of efavirenz and artemether and their
interaction. The main pharmacokinetic variables for differ-
ent dosing strategies were simulated and the effect of
efavirenz on artemether clearance and bioavailability has
been quantified. The clarification of the magnitude of drug-
drug interaction between efavirenz and artemether is
clinically relevant since sub-therapeutic artemether concen-
trations can lead to therapeutic failure. The IVIVE
approach can be applied to not only to predict the utility of
potential dose adjustments but also for the management of
drug-drug interactions in special populations such as paedi-
atric, elderly and patients affected by multiple morbidities.
This simulation approach can be viewed as a paradig-
matic example demonstrating that IVIVE can be used to
investigate clinically relevant ‘what-if ’ questions and to in-
form the design of prospective clinical trials. As previously
demonstrated in numerous studies, IVIVE can be used to
predict pharmacokinetics in numerous diseases, investi-
gating molecular mechanisms which can impact drug dis-
position and to inform future clinical studies. Wider
application of IVIVE could help researchers gain a better
understanding of the molecular mechanisms underpinning
variability in drug disposition, an essential condition to fur-
ther improve the quality of future research projects. Future
application of this approach may include other drug-drug
interaction simulations, dose optimisation in special popu-
lations, prediction of pharmacogenetic effects and opti-
misation of treatment strategies.
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